ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Hodgkin Lymphoma in Louisville, KY

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Lymphoma
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Cancer

Non-Hodgkin Lymphoma trials near Louisville, KY, USA:

A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

This is a Phase 1/2 study of imvotamab in adult subjects with relapsed or refractory B-cell Non-Hodgkin Lymphoma. This stu...

Active, not recruiting
Marginal Zone Lymphoma
Mantle Cell Lymphoma
Drug: imvotamab

Phase 1, Phase 2

IGM Biosciences

Louisville, Kentucky, United States and 26 other locations

The purpose of this study was to evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in pr...

Active, not recruiting
Lymphoma,Non-Hodgkin
Drug: Placebo
Drug: Copanlisib (Aliqopa, BAY80-6946)

Phase 3

Bayer
Bayer

Louisville, Kentucky, United States and 188 other locations

Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL.Part 2: To characterize th...

Active, not recruiting
Non Hodgkin Lymphoma
Drug: acalabrutinib
Drug: rituximab (IV)

Phase 1, Phase 2

Acerta Pharma
Acerta Pharma

Louisville, Kentucky, United States and 31 other locations

CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non...

Enrolling
Refractory B-Cell Non-Hodgkin Lymphoma
B Cell Lymphoma
Genetic: CB-010
Drug: Cyclophosphamide

Phase 1

Caribou Biosciences

Louisville, Kentucky, United States and 29 other locations

to define the recommended dose for phase 2 for the combination.The study is focused on patients with relapsed or refractory aggressive B-cell non...

Enrolling
B-cell Non-Hodgkins Lymphoma (B-NHL)
Drug: REGN5837
Drug: Odronextamab

Phase 1

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Louisville, Kentucky, United States and 13 other locations

The purpose of this study is to evaluate the safety and preliminary efficacy of ATA3219 in participants with relapsed/refractory (R/R) B-cell non...

Enrolling
DLBCL Arising From Transformed Indolent Lymphoma
High-grade B-cell Lymphoma
Drug: ATA3219

Phase 1

Atara Biotherapeutics

Louisville, Kentucky, United States

clinical trial will enroll patients with relapsed/refractory non-Hodgkin lymphoma of B-cell origin and is conducted in two...

Enrolling
Non Hodgkin Lymphoma
Drug: Rituximab
Drug: Cyclophosphamide

Phase 1, Phase 2

Artiva Biotherapeutics

Louisville, Kentucky, United States and 20 other locations

Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab in Subjects with Indolent B-Cell Non...

Enrolling
Indolent B-Cell Non-Hodgkin Lymphoma
Biological: BI-1206

Phase 1, Phase 2

BioInvent International

Louisville, Kentucky, United States and 21 other locations

bispecific antibody, in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) who have received 2 or mo...

Enrolling
B-cell Non Hodgkin Lymphoma
Follicular Lymphoma
Drug: AZD0486 IV

Phase 1

AstraZeneca
AstraZeneca

Louisville, Kentucky, United States and 28 other locations

This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of IMPT-314, a bispecific chimeric antigen receptor (CAR) targ...

Enrolling
Relapsed Non-Hodgkin Lymphoma
Refractory Non-Hodgkin Lymphoma
Drug: IMPT-314

Phase 1, Phase 2

ImmPACT Bio

Louisville, Kentucky, United States and 19 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems